The cardiovascular safety profile makes GLP-1 medications particularly attractive for people with diabetes who also have heart disease risk factors
The Wikipedia overview of Retatrutide provides additional trial context
Certain states have additional requirements due to telehealth regulations: States Requiring Pre-Prescription Telehealth Appointment : Kansas, Indiana, Mississippi, New Mexico, Oklahoma, and West Virginia States Limited to Injectable Formulations Only : Alabama and California (tablets not available per state law) State availability and telehealth prescribing rules change frequently
Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.
Your medication is shipped discreetly to your door, along with easy-to-follow instructions to get you started
Retatrutide is an investigational compound that has not been approved by the FDA, so it does not belong in a sentence describing which agents the agency restricts to prescription status alongside semaglutide and tirzepatide
